Syndax Pharmaceuticals (NASDAQ:SNDX) CFO Keith Goldan Sells 1,177 Shares

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Keith Goldan sold 1,177 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $18.99, for a total transaction of $22,351.23. Following the completion of the sale, the chief financial officer directly owned 139,252 shares of the company’s stock, valued at $2,644,395.48. The trade was a 0.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Syndax Pharmaceuticals Stock Down 2.4%

SNDX stock opened at $18.39 on Wednesday. The stock has a market capitalization of $1.63 billion, a P/E ratio of -6.59 and a beta of 0.38. The company has a debt-to-equity ratio of 8.26, a quick ratio of 5.06 and a current ratio of 5.47. Syndax Pharmaceuticals, Inc. has a one year low of $8.59 and a one year high of $25.59. The company has a 50 day moving average price of $22.13 and a two-hundred day moving average price of $21.20.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Thursday, April 30th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.11. The firm had revenue of $64.86 million during the quarter, compared to analysts’ expectations of $69.76 million. Syndax Pharmaceuticals had a negative net margin of 111.88% and a negative return on equity of 256.65%. Syndax Pharmaceuticals’s revenue for the quarter was up 224.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.98) EPS. As a group, sell-side analysts expect that Syndax Pharmaceuticals, Inc. will post -1.66 EPS for the current year.

Institutional Trading of Syndax Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Smartleaf Asset Management LLC grew its stake in shares of Syndax Pharmaceuticals by 2,698.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,659 shares of the company’s stock valued at $55,000 after buying an additional 2,564 shares during the period. Larson Financial Group LLC grew its stake in shares of Syndax Pharmaceuticals by 192.2% during the 3rd quarter. Larson Financial Group LLC now owns 2,922 shares of the company’s stock valued at $45,000 after buying an additional 1,922 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Syndax Pharmaceuticals during the 3rd quarter valued at $53,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Syndax Pharmaceuticals by 26.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,223 shares of the company’s stock valued at $89,000 after buying an additional 893 shares during the period. Finally, Lazard Asset Management LLC purchased a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter valued at $66,000.

Analyst Upgrades and Downgrades

Several research firms have commented on SNDX. The Goldman Sachs Group lifted their target price on shares of Syndax Pharmaceuticals from $28.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, April 1st. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Syndax Pharmaceuticals in a research note on Friday, May 22nd. Wall Street Zen raised shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, March 8th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $40.00 target price (down from $48.00) on shares of Syndax Pharmaceuticals in a research note on Monday, March 30th. Finally, Mizuho lowered their target price on shares of Syndax Pharmaceuticals from $45.00 to $43.00 and set an “outperform” rating for the company in a research note on Tuesday, March 31st. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Syndax Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.55.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.